Ontogeny of Measles Immunity in Infants
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00240916. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Ontogeny of Vaccine-Induced Measles Immunity Child Participant-6 and 9 Months
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving MMR-II. Responses of infants receiving an early two dose measles vaccine regimen with the first dose given at 6 or 9 months followed by a second dose administered at 12 months will also be compared to infants given a single dose at 12 months of age (Table 2). The current approved regimen for measles vaccination is a first vaccination at 12-15 months and a subsequent vaccination at school entry. A secondary endpoint of this study will be to assess the safety of measles vaccine administered as Attenuvax at 6 or 9 months of age and in an early two dose measles vaccine regimen with Attenuvax administered at 6 or 9 months followed by MMR-II at 12 months of age.
Study identification
- NCT ID
- NCT00240916
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 750 participants
Conditions and interventions
Conditions
Interventions
- Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous) Biological
- MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous) Biological
Biological
Eligibility (public fields only)
- Age range
- 6 Months and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1993 (Type not available)
- Primary completion
- Jul 2011 (Actual)
- Completion
- Jul 2013 (Actual)
- Last update posted
- Jun 9, 2022
1993 – 2013
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Alto Medical Foundation/Department of Pediatrics | Palo Alto | California | 94301 | — |
| Stanford University School of Medicine | Stanford | California | 94305 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00240916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2022 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.